Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Internet Explorer is no longer a supported browser.

This website may not display properly with Internet Explorer. For the best experience, please use a more recent browser such as the latest versions of Google Chrome, Microsoft Edge, and/or Mozilla Firefox. Thank you.

Your Environment. Your Health.


Export to Word (
Principal Investigator: Lee, Marietta Y.
Institute Receiving Award New York Medical College
Location Valhalla, NY
Grant Number R56ES014737
Funding Organization National Institute of Environmental Health Sciences
Award Funding Period 01 Dec 2007 to 31 Jan 2022
DESCRIPTION (provided by applicant): Cancers with germline or somatic mutations of BRCA1/2 have compromised DNA repair pathway, homologous recombination (HR) deficiency. These cancers have a unique response to PARP inhibitors and consequently BRCA1/2 mutations are markers to determine treatment options for breast and ovarian cancers. There is an urgent need to identify additional markers in all cancers that indicate deficiency in HR and consequently application of PARP inhibitors for these cancers. The DNA homologous repair pathway requires many proteins and enzymes to coordinate the repair of DNA double-stranded breaks. Among them, a DNA polymerase is essential for the key step of D-loop extension. In this application, we hypothesize that a specific form of DNA polymerase , Pol 4, is required for HR. Thus, cancer cells without Pol 4 are HR deficient and sensitive to PARP inhibition. The hypothesis is based on our work in characterization of the enzymatic properties of Pol 4, especially the ability in strand displacement synthesis. Indeed, it has been shown that the majority of small cell lung cancer (SCLC) cells lack Pol 4, which is also supported by our preliminary data. The main goal of this project is to test our central hypothesis that Pol 4 is the key form of polymerase that can perform D-loop extension to facilitate homologous recombination repair of DNA double-stranded breaks. Cancer cells deficient in Pol 4 are HR deficient and amendable to PARP inhibition. Specifically, this project will 1) Establish that Pol 4 is required for homologous recombination and the consequences of Pol 4-deficiency to genomic stability; 2) Characterize the unique response of Pol 4 deficient cells to chemotherapeutic agents and PARP inhibitors; 3) Elucidate the regulation of D-loop extension by Pol d4 by 3’-5’ helicases, including BLM, WRN and DHX9. The proposed research is innovative as we employ multidisciplinary approaches that include cellular studies and enzymatic characterization to elucidate the underlying mechanisms of Pol 4 function in D-loop extension. The insight from how changes in subunit composition of Pol  affect its function in DNA replication and repair is innovative. Completion of this proposal will be a significant contribution to our understanding of how DNA damages lead to carcinogenesis due to alteration of Pol  quaternary structure. The results in this proposal can potentially change clinical practice in cancer treatment and define a new class of cancers that can be treated with PARP inhibitors.
Science Code(s)/Area of Science(s) Primary: 07 - Human Genetics/Gene X Environment Interaction
Secondary: 01 - Basic Cellular or Molecular processes
Publications See publications associated with this Grant.
Program Officer Kimberly Mcallister
to Top